4D Molecular Therapeutics is a clinical-stage gene therapy company engaging the development of product candidates using its targeted and evolved adeno-associated viruses vectors. Co. has built a portfolio of gene therapy product candidates, with five product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa, 4D-150 for the treatment of wet age-related macular degeneration, 4D-110 for the treatment of choroideremia, 4D-310 for the treatment of Fabry disease, and 4D-710 for the treatment of cystic fibrosis lung disease. The FDMT stock yearly return is shown above.
The yearly return on the FDMT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the FDMT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|